This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

It is planned to enroll 14 subjects who will receive single oral doses of active IMP in a sequential manner over 5 periods, with a minimum of 7days between dosing in each period.

Inclusion Criteria:

• Healthy males or non-pregnant, non-lactating healthy females
• Body mass index (BMI) of 18.0 to 32.0kg/m² and a body weight>50kg as measured at screening
• Must be willing and able to communicate and participate in the whole study
• Must provide written informed consent
• Must agree to adhere to the contraception requirements

Exclusion Criteria:

• Subjects who have received any IMP formulation in a clinical research study within the 90 days prior to Period 1, Day 1
• History of any drug or alcohol abuse in the past 2 years
• Subjects with pregnant or lactating partners
• Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are allowed.
• History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
• Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
• Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4g of paracetamol per day or HRT/hormonal contraception) in the 14 days before first IMP administration.